NY-MINISTRY-OF-CULTURE
6.9.2022 15:36:41 CEST | Business Wire | Press release
Ukraine President Volodymyr Zelenskyy virtually rang the Opening Bell of the New York Stock Exchange (NYSE) today, inviting businesses around the world to invest in the future of Ukraine.
The President’s appearance marked the launch of Advantage Ukraine, an initiative focused on attracting future investment into the country by showcasing the breadth of opportunity across sectors including agriculture, technology, education, and the creative industries as well as the tremendous potential offered by the country’s natural resources and educated workforce.
To drive engagement with potential investors, the government of Ukraine today launched www.advantageukraine.com featuring hundreds of growth opportunities and highlighting existing and future incentives to attract foreign direct investment. Ukraine is already a leader in the science and technology sectors and poised to grow, offering a well-educated, English-speaking workforce with in-demand STEM capabilities. Today, Ukraine has more graduates with degrees in technology than any other European country and has 240,000 citizens employed in the IT sector which is forecast to increase to 450,000 by 2024. Additionally, Ukraine leads among CEE countries in R&D activities and IT outsourcing.
President H.E. Volodymyr Zelenskyy said: “Even as we strive to secure our freedom and deliver relief to our proud people, I am urgently planning a prosperous future for Ukraine. The Advantage Ukraine program asks foreign investors and companies who have vision and courage to join us, and we will match the world’s best companies with superior growth opportunities. Bold businesses who see the potential in our country will help to realize the economic potential of Ukraine while benefitting from untapped growth opportunities.”
The $400+bn in investment options featured on AdvantageUkraine.com span public private partnerships, privatization and private ventures. A USAID-supported project team of investment bankers and researchers appointed by Ukraine’s Ministry of Economy will work with businesses interested in investing.
Lynn Martin, President of NYSE Group, said: “As the largest exchange globally, we stand for freedom, investor protection and unfettered access to capital. We are pleased to welcome President Zelenskyy virtually to the NYSE bell podium, a symbol of the freedom and opportunity our U.S. capital markets have enabled around the globe. We are honored the President has chosen the NYSE to mark the kickoff of Advantage Ukraine and engage with the world’s business community.”
To create a safe, transparent environment for business engagement, Ukraine is actively pursuing investment guarantees from both the G7 and European Union, reforming the country’s tax system, and establishing a legal framework. The country has already adopted rules and legislations to allow companies to build a transparent corporate structure, attract foreign investment more easily, and use additional mechanisms to protect intangible assets. Favorable conditions will make it possible to establish Ukraine as the most powerful IT hub in Central and Eastern Europe, and to quickly and effectively implement innovative business ideas.
Mark Read, CEO, WPP, said: “With a thriving technology sector and renowned creative industries, Ukraine has the potential to grow into a global center of innovation. At WPP, we are excited by the growth possibilities that Ukraine presents across many of the sectors represented by our client base, and the opportunities for the private sector to play a pivotal role in re-building the country’s economy.”
Sundar Pichai, CEO of Google and Alphabet, said: “I was humbled by the resilience and talent of the Ukrainian startup founders I met while visiting Google’s campus in Warsaw earlier this year. As we continue to help support Ukraine through our platforms and tools — and counter dangerous misinformation online — it’s important that we also support Ukrainian businesses working to sustain and grow their economy. I commend President Zelenskyy on the launch of Advantage Ukraine and the positive vision it lays out for Ukraine’s economic future.”
Brad Smith, President and Vice Chair, Microsoft Corporation, said: “Ukraine offers tremendous talent and expertise to companies looking to invest in technology. It’s why Microsoft has invested more than $200m over the past five years and why we are excited about the digital transformation Ukraine’s technology sector will deliver.”
Dr. Lori Esposito Murray, President, The Committee for Economic Development, the public policy center of the Conference Board, comprised of chief executive officers and key executives of leading U.S. companies, said: “The Committee for Economic Development (CED), which is committed to the goal of sustaining capitalism, commends the efforts of President Zelenskyy, the Ukrainian government, and global business leaders to ensure foreign direct investment in Ukraine, as the country strives to unleash its economic talent and rebuild for an independent and prosperous future. CED’s mission since its founding in 1942, has been to help plot a course for prosperity based on the principles of a rules based, free market, economic order and democratic institutions - including leading the establishment of the Marshall Plan, which facilitated the redevelopment of Europe following the devastation of World War II and establishing a stable global financial system with the Bretton Woods Agreement. As Ukraine looks to establish the necessary conditions for investment, the public and private sectors have a critical opportunity to work together to create sustainable economic growth, which we actively support.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220905005440/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
